Overview

Gender

female

Investor Type

Investment Partner

Regina Hodits joined Wellington Partners in spring 2010 as a part-time advisor and stepped up to General Partner in January 2011. Since 2000, she has become an influential investor in the European venture capital industry, focusing on early-stage and growth deals in Life Sciences. Her industry experience and her strong scientific background will help the Wellington Life Sciences team to strengthen its position in the European investment market.

Until January 2010, Regina led the life sciences efforts of Atlas Venture in Europe, a leading transatlantic venture capital firm. As a Partner at Atlas Venture, she led numerous financing rounds and was the founding investor in Bicycle Therapeutics, Fibrex, F-star and Jenavalve. In addition, she served on the Board of Egalet, Lumavita, Novamed and Protaffin and is an external director at GlaxoSmithKline's (GSK) Respiratory CEDD. Regina was also on the Board of U3 Pharma, which was acquired by Daiichi Sankyo Co.,Ltd. in 2008.

From 2000 to 2004, while working for Apax Partners, she was responsible for healthcare investments in Germany and was closely involved in investments such as Genmab, Silence Therapeutics and Wilex. She started to build her extensive network in the global healthcare industry during her tenure at McKinsey from 1997 to 2000.